CN105457968A - Innocent treatment method for antibiotic fungi residues - Google Patents
Innocent treatment method for antibiotic fungi residues Download PDFInfo
- Publication number
- CN105457968A CN105457968A CN201510788180.9A CN201510788180A CN105457968A CN 105457968 A CN105457968 A CN 105457968A CN 201510788180 A CN201510788180 A CN 201510788180A CN 105457968 A CN105457968 A CN 105457968A
- Authority
- CN
- China
- Prior art keywords
- antibiotic
- bacterium dregs
- antibiotic bacterium
- innocent treatment
- fungi residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 49
- 241000233866 Fungi Species 0.000 title abstract 7
- 241000894006 Bacteria Species 0.000 claims description 75
- 238000003756 stirring Methods 0.000 claims description 30
- 230000009849 deactivation Effects 0.000 claims description 5
- 229940126575 aminoglycoside Drugs 0.000 claims description 4
- 230000001857 anti-mycotic effect Effects 0.000 claims description 4
- 239000002543 antimycotic Substances 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 229940041033 macrolides Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 239000003895 organic fertilizer Substances 0.000 abstract description 2
- 239000002912 waste gas Substances 0.000 abstract description 2
- 239000003674 animal food additive Substances 0.000 abstract 1
- 239000000701 coagulant Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 15
- 238000009413 insulation Methods 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000003513 alkali Substances 0.000 description 11
- 239000002893 slag Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002920 hazardous waste Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 3
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 229930189077 Rifamycin Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 229960004602 capreomycin Drugs 0.000 description 2
- NUAQIRUAZSJTAI-TYIWBIPUSA-N chembl2374194 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 NUAQIRUAZSJTAI-TYIWBIPUSA-N 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 108700023456 demethylvancomycin Proteins 0.000 description 2
- 229960002222 dihydrostreptomycin Drugs 0.000 description 2
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960003292 rifamycin Drugs 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 229940063650 terramycin Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- NJCUSQKMYNTYOW-MWUYRYRWSA-N enramicina Chemical compound O.N1C(=O)NC(=O)C(C=2C=C(Cl)C(O)=C(Cl)C=2)NC(=O)C(CO)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(CC2N=C(N)NC2)NC(=O)C(CCCNC(N)=O)NC(=O)C(C(C)O)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C(C)O)NC(=O)N(CCCCN)C(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)/C=C/C=C/CCCCC(C)CC)C(C)OC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C)NC(=O)C1CC1CNC(N)=N1 NJCUSQKMYNTYOW-MWUYRYRWSA-N 0.000 description 1
- 108700041171 enramycin Proteins 0.000 description 1
- 229950003984 enramycin Drugs 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 229930191952 glutinosin Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/40—Destroying solid waste or transforming solid waste into something useful or harmless involving thermal treatment, e.g. evaporation
- B09B3/45—Steam treatment, e.g. supercritical water gasification or oxidation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B5/00—Operations not covered by a single other subclass or by a single other group in this subclass
Landscapes
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processing Of Solid Wastes (AREA)
Abstract
The invention discloses an innocent treatment method for antibiotic fungi residues. The innocent treatment method is characterized in that the antibiotic fungi residues are inactivated under conditions with a pH value of 8-11 and a temperature of 90-100 DEG C. According to the method, the fungi residues are inactivated, so that the antibiotics in the antibiotic fungi residues lose activity, and the inactivated fungi residue mycelia comprise microorganism-containing cells, a coagulant aid and residual nutritional ingredients, and can be used for an organic fertilizer or a feed additive. In a treatment process, waste gas is not generated and treatment cost is relatively low, and the treated fungi residues can be reasonably reutilized, so that certain economic benefits can be generated, and therefore, the innocent treatment method has the characteristics of being energy-saving, environmentally-friendly, pollution-free, relatively low in cost and the like.
Description
Technical field
The present invention relates to a kind of hazardous waste disposal method, especially a kind of method for innocent treatment of antibiotic bacterium dregs danger wastes.
Background technology
China is production of raw medicine big country, and antibiotic pharmaceutical industry scale grows stronger day by day, and has occupied the position of world's antibiotic yield first at present.Antibiotic bacterium dregs is the solid waste produced in fermentation class medicine material medicine production process, also referred to as the dregs of a decoction or albumen slag; Primarily of some culture medium carriers composition added in the mycelia of fermentation generation, biological metabolic waste and production process process, its key component is protein, aliphatic acid, amino acid, cellulose, carbohydrate and various inorganic salts etc.
The main pollution of antibiotic bacterium dregs is presented as the following aspects: (1) foul smell: because the moisture content of antibiotic bacterium dregs is higher, and many enterprises of China focus on after usually needing to stack a period of time in the open.Store up in process, antibiotic bacterium dregs can liquefy, mycelium can self-dissolving fouling.(2) impact on health of residual antibiotic: the main harm characteristic of microbiological pharmacy bacterium slag is residual drug component; Major part antibiotic can transmit in by food chain, finally has influence on human body, produces interference to body normal activity.(3) ecology influence: antibiotic residual in bacterium slag can enter into soil or water body, can impact environmental organism.(4) bring out and propagate a large amount of drug-fast bacteria: increasing evidence shows that antibiotic in use can induce the resistant strain producing and have drug resistance, and generation and the diffusion couple environmental and human health impacts of bacterial drug resistance cause potential threat.
Regulation in " National Hazard discarded object register " that on August 1st, 2008 implements, " mother liquor in chemicals production of raw medicine process and reactive group or culture medium refuse (refuse code 271-002-02) " is hazardous waste.Antibiotic bacterium dregs is defined as hazardous waste, should manage according to hazardous waste.At present, the method one disposed it is buried, and two is burn.Buried contaminated soil and underground water; Burning exist ability little, do not burn, expense too high fever does not rise, and atmosphere pollution must not burn.Optimum disposal method is there is no for this kind of danger wastes of antibiotic bacterium dregs.
Summary of the invention
The technical problem to be solved in the present invention is to provide the method for innocent treatment of a kind of low cost, free of contamination antibiotic bacterium dregs danger wastes.
For solving the problems of the technologies described above, the technical solution used in the present invention is: by antibiotic bacterium dregs deactivation under the condition of pH8 ~ 11, temperature 90 ~ 100 DEG C.
Inactivation time of the present invention is 2 ~ 3h.
The present invention, under stirring, adopts steam to carry out deactivation.
Antibiotic of the present invention is four lopps, aminoglycosides, polypeptide class, macrolides, antimycotic and/or treating tuberculosis class.
The beneficial effect adopting technique scheme to produce is: the present invention is by the deactivation of bacterium slag, Degradation of Antibiotics is wherein lost activity, the bacterium slag mycelium of inactivation includes the cell of microorganism, flocculation aid and residue nutritional labeling, namely can be used for organic fertilizer or feed addictive.The present invention can not produce waste gas in processing procedure, disposal cost is lower, and the bacterium slag after process can reasonably utilize again, can produce certain economic benefit.Therefore, the present invention has energy-conserving and environment-protective, pollution-free, cost is lower and resource obtains the features such as Appropriate application.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further detailed explanation.
The processing step of the method for innocent treatment of this antibiotic bacterium dregs is: (1) adopts acid or alkali to be 8 ~ 11 by antibiotic bacterium dregs at pH, stirs; Described acid is hydrochloric acid, sulfuric acid and/or nitric acid, and described alkali is NaOH and/or potassium hydroxide; (2) under stirring, steam heated to 90 ~ 100 DEG C are adopted, heating and thermal insulation 2 ~ 3h.For the treatment of the solid waste-bacterium slag produced in the antibiotics production processes such as four lopps, aminoglycosides, polypeptide class, macrolides, antimycotic, treating tuberculosis class.Wherein, four lopps mainly comprise terramycin, tetracycline, aureomycin etc., and pH is preferably 8 ~ 10.3; Aminoglycosides mainly comprises streptomycin sulphate, dihydrostreptomycin (streptomycin sulphate), gentamicin sulphate, kanamycin sulfate, neomycin, spectinomycin, TOB etc., and pH is preferably 9 ~ 10.5; Polypeptide class mainly comprises vancomycin, many glutinosins, demethyl vancomycin, bacitracin, cyclosporin A etc., and pH is preferably 10 ~ 11; Macrolides comprises lincomycin, spiramvcin etc., and pH is preferably 10 ~ 11; Antimycotic mainly comprises griseofulvin, nystatin, amphotericin B, Natamycin etc., and pH is preferably 10 ~ 11; Treating tuberculosis class mainly comprises rifamycin, rifamicina, capreomycin etc., and pH is preferably 9 ~ 10.5.
Embodiment 1: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing terramycin generation is put into retort, by alkali adjusted to ph to 9, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 95 DEG C, insulation 2h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 2: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing tetracycline generation is put into retort, by alkali adjusted to ph to 8, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 90 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 3: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing aureomycin generation is put into retort, by alkali adjusted to ph to 10.3, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 90 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 4: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing dihydrostreptomycin generation is put into retort, by sour adjusted to ph to 9, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 95 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 5: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing gentamicin sulphate generation is put into retort, by alkali adjusted to ph to 10.5, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 100 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 6: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing spectinomycin generation is put into retort, by sour adjusted to ph to 9.5, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 98 DEG C, insulation 3h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 7: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing vancomycin generation is put into retort, by alkali adjusted to ph to 11, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 93 DEG C, insulation 2h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 8: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing the generation of demethyl vancomycin is put into retort, by alkali adjusted to ph to 10.7, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 95 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 9: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing enramycin generation is put into retort, by alkali adjusted to ph to 10, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 96 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 10: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing griseofulvin generation is put into retort, by sour adjusted to ph to 11, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 93 DEG C, insulation 3h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 11: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing amphotericin B generation is put into retort, by sour adjusted to ph to 10, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 97 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 12: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing rifamycin generation is put into retort, by alkali adjusted to ph to 9, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 96 DEG C, insulation 2.5h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Embodiment 13: the concrete technology of the method for innocent treatment of this antibiotic bacterium dregs is as described below.
The antibiotic bacterium dregs producing capreomycin generation is put into retort, by alkali adjusted to ph to 10.5, stirs; Under stirring, adopt steam heated, antibiotic bacterium dregs in tank is heated to 92 DEG C, insulation 3h.
Antibiotic bacterium dregs after treatment adopts " Chinese Pharmacopoeia " (version in 2010) antibiotic-microbial assay-cylinder-plate method to measure, and it does not form inhibition zone.
Claims (4)
1. a method for innocent treatment for antibiotic bacterium dregs, is characterized in that: by antibiotic bacterium dregs pH be 8 ~ 11, deactivation under the condition of temperature 90 ~ 100 DEG C.
2. the method for innocent treatment of antibiotic bacterium dregs according to claim 1, is characterized in that: described inactivation time is 2 ~ 3h.
3. the method for innocent treatment of antibiotic bacterium dregs according to claim 1, is characterized in that: under stirring, adopts steam to carry out deactivation.
4. the method for innocent treatment of the antibiotic bacterium dregs according to claim 1,2 or 3, is characterized in that: described antibiotic is four lopps, aminoglycosides, polypeptide class, macrolides, antimycotic and/or treating tuberculosis class.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510788180.9A CN105457968B (en) | 2015-11-17 | 2015-11-17 | The method for innocent treatment of antibiotic bacterium dregs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510788180.9A CN105457968B (en) | 2015-11-17 | 2015-11-17 | The method for innocent treatment of antibiotic bacterium dregs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105457968A true CN105457968A (en) | 2016-04-06 |
| CN105457968B CN105457968B (en) | 2018-07-13 |
Family
ID=55596376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510788180.9A Expired - Fee Related CN105457968B (en) | 2015-11-17 | 2015-11-17 | The method for innocent treatment of antibiotic bacterium dregs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105457968B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106110562A (en) * | 2016-06-29 | 2016-11-16 | 上海化工研究院 | A kind of for removing the method for griseofulvin in biological medicine waste residue |
| CN106480103A (en) * | 2016-12-07 | 2017-03-08 | 中国科学院生态环境研究中心 | A kind of detoxification method of ferment antibiotics bacteria residue |
| CN106480104A (en) * | 2016-12-07 | 2017-03-08 | 中国科学院生态环境研究中心 | A kind of preprocess method of ferment antibiotics bacteria residue |
| CN108164292A (en) * | 2017-12-25 | 2018-06-15 | 伊犁川宁生物技术有限公司 | A kind of method that organic fertilizer is prepared using antibiotic bacterium dregs |
| CN109628497A (en) * | 2018-12-10 | 2019-04-16 | 河北科技大学 | A kind of antibiotic bacterium dregs recycling processing method |
| CN113458110A (en) * | 2020-03-30 | 2021-10-01 | 伊犁川宁生物技术有限公司 | Novel harmless treatment method for macrolide antibiotic fermentation mushroom dregs |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009255074A (en) * | 2008-04-11 | 2009-11-05 | Hanbat National Univ Industry-Academic Cooperation Foundation | Anaerobic integration process apparatus for organic waste treatment |
| CN102424636A (en) * | 2011-09-27 | 2012-04-25 | 陕西绿盾生物制品有限责任公司 | Method for producing organic fertilizer by polyoxin residues |
| CN103230659A (en) * | 2013-03-22 | 2013-08-07 | 宋生 | Process for treatment of beta-lactam ring antibiotic filter residue |
| CN103831283A (en) * | 2014-02-25 | 2014-06-04 | 北京观澜科技有限公司 | Method for harmless treatment of ferment antibiotic residues |
| CN103923734A (en) * | 2014-05-04 | 2014-07-16 | 天津理工大学 | Method for regenerating used oil by adopting antibiotic waste mushroom dreg biomass charcoal |
-
2015
- 2015-11-17 CN CN201510788180.9A patent/CN105457968B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009255074A (en) * | 2008-04-11 | 2009-11-05 | Hanbat National Univ Industry-Academic Cooperation Foundation | Anaerobic integration process apparatus for organic waste treatment |
| CN102424636A (en) * | 2011-09-27 | 2012-04-25 | 陕西绿盾生物制品有限责任公司 | Method for producing organic fertilizer by polyoxin residues |
| CN103230659A (en) * | 2013-03-22 | 2013-08-07 | 宋生 | Process for treatment of beta-lactam ring antibiotic filter residue |
| CN103831283A (en) * | 2014-02-25 | 2014-06-04 | 北京观澜科技有限公司 | Method for harmless treatment of ferment antibiotic residues |
| CN103923734A (en) * | 2014-05-04 | 2014-07-16 | 天津理工大学 | Method for regenerating used oil by adopting antibiotic waste mushroom dreg biomass charcoal |
Non-Patent Citations (2)
| Title |
|---|
| PU WANG等: "Effect of Heat Treatments on Stability of Penicilling in Waste Penicillium Chrysogenum", 《ADVANCES IN CHEMICAL SCIENCE》 * |
| 刘玲: "从青霉素菌丝体中提取蛋白、麦角固醇、壳聚糖的工艺研究", 《中国优秀硕士学位论文全文数据库工程科技I辑》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106110562A (en) * | 2016-06-29 | 2016-11-16 | 上海化工研究院 | A kind of for removing the method for griseofulvin in biological medicine waste residue |
| CN106110562B (en) * | 2016-06-29 | 2020-08-11 | 上海化工研究院有限公司 | Method for removing griseofulvin in biological medicine waste residue |
| CN106480103A (en) * | 2016-12-07 | 2017-03-08 | 中国科学院生态环境研究中心 | A kind of detoxification method of ferment antibiotics bacteria residue |
| CN106480104A (en) * | 2016-12-07 | 2017-03-08 | 中国科学院生态环境研究中心 | A kind of preprocess method of ferment antibiotics bacteria residue |
| CN106480103B (en) * | 2016-12-07 | 2019-07-26 | 中国科学院生态环境研究中心 | A kind of detoxification method of ferment antibiotics bacteria residue |
| CN106480104B (en) * | 2016-12-07 | 2019-09-06 | 中国科学院生态环境研究中心 | A kind of preprocess method of ferment antibiotics bacteria residue |
| CN108164292A (en) * | 2017-12-25 | 2018-06-15 | 伊犁川宁生物技术有限公司 | A kind of method that organic fertilizer is prepared using antibiotic bacterium dregs |
| CN109628497A (en) * | 2018-12-10 | 2019-04-16 | 河北科技大学 | A kind of antibiotic bacterium dregs recycling processing method |
| CN109628497B (en) * | 2018-12-10 | 2022-05-03 | 河北科技大学 | Resourceful treatment method for antibiotic mushroom dregs |
| CN113458110A (en) * | 2020-03-30 | 2021-10-01 | 伊犁川宁生物技术有限公司 | Novel harmless treatment method for macrolide antibiotic fermentation mushroom dregs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105457968B (en) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105457968A (en) | Innocent treatment method for antibiotic fungi residues | |
| Hua et al. | Pretreatment of non-sterile, rotted silage maize straw by the microbial community MC1 increases biogas production | |
| CN105294312A (en) | Method for preparing liquid biofertilizer through organic waste liquid | |
| CN102391950B (en) | Food waste deodorization composite bacteria and preparation method thereof | |
| CN104560816B (en) | Bacillus licheniformis with biomass hydrolase activity and application thereof | |
| CN103194804B (en) | Energy-saving environment-friendly biological degumming technology | |
| CN104651274A (en) | Method for performing high-density culture of bacillus | |
| CN102326668B (en) | Method for anaerobically degrading feather keratin with microbial strain 18D-TA | |
| CN103159513A (en) | Method for producing biological bactericide by using paper-making wastewater | |
| CN110981563A (en) | Treatment method and application of antibiotic fungi residues | |
| CN104651339B (en) | The culture medium and its fermentation process of microvesicle Pseudomonas fermenting and producing algin catenase | |
| CN107500499A (en) | A kind of method for promoting sludge anaerobic fermentation using biosurfactant | |
| CN106465789A (en) | A kind of antibiotic bacterium dregs pectinase enzymatic hydrolysis method | |
| CN107916241A (en) | The composite bacteria agent and its application of fortimicin concentration and drug resistant gene in a kind of reduction composting process | |
| CN106811489A (en) | A kind of open production method of lectic acid of the lactic acid bacteria based on lactic acid producing pediocin | |
| CN101659951B (en) | Immobilized cultivation method for 'microbiological straw additive' | |
| CN105803003A (en) | Rapid starting method for fermentation production of biogas from Chinese herb residues | |
| Liu et al. | Effects of pretreatment on the microbial community and l-lactic acid production in vinasse fermentation | |
| CN105820958A (en) | Gentamicin degradation fungus and application thereof | |
| Prasad et al. | Optimization of cellulase production from a novel bacterial isolate Mesorhizobium sp. from marine source | |
| CN103193368A (en) | Method for promoting excess sludge microorganisms to hydrolyze by using thermophilic geobacillus sp | |
| CN102899268A (en) | Vancomycin strain and method for producing vancomycin through vancomycin strain fermentation | |
| CN104529583A (en) | Method for producing organic fertilizer by treating sludge by use of microbial technology | |
| CN104178434A (en) | Method for preparing industrial yeast by use of antibiotic mushroom dregs | |
| CN104759445B (en) | A kind of shield shell mould fermentation technique harmless treatment dreg method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180713 Termination date: 20211117 |